Zomedica (ZOM) Investor presentation summary

Mission and market opportunity

• Focused on delivering innovative diagnostic and therapeutic technologies to veterinarians, aiming to improve pet care, client satisfaction, and veterinary practice profitability.

• Significant market opportunity driven by increasing pet ownership, younger pet owners, and a strong human-animal bond, with the U.S. veterinary services market valued at $62B in 2023.

• Portfolio addresses critical animal health needs with advanced therapeutic devices and diagnostic platforms.

• Global commercial channels and R&D/M&A capabilities support expansion and adoption.

• Operational efficiencies and self-funded growth trajectory supported by strong liquidity.

Product portfolio and innovation

• Therapeutic devices include PulseVet shock wave system, Assisi tPEMF therapy, and VETIGEL hemostatic gel, each targeting specific clinical needs and generating recurring revenue.

• Diagnostic platforms such as TRUVIEW AI microscope, TRUFORMA point-of-care system, and VETGuardian remote monitoring offer advanced workflow and clinical decision support.

• Products are distributed through direct sales, e-commerce, and international channels, with ongoing product upgrades and new assay launches.

• Emphasis on leveraging AI and digital solutions to enhance platform capabilities and customer engagement.

Financial performance and growth

• Achieved sustained revenue growth from $4.1M in 2021 to $32M projected for 2025, with gross margins ranging from 67% to 74%.

• Maintained strong liquidity, ending 2024 with $71.4M and 2025 with $53.3M in cash.

• Operating burn managed at $4-5M per quarter, with cash flow positive at low market penetration.

• Growth fueled by acquisitions, R&D, and manufacturing investments.